Recently, our company’s holding subsidiary, Huonland, received the “Notice from the Beijing Municipal Administration for Drug Supervision on the Results of the Pharmaceutical GMP Inspection.” Its single-dose production line (Line 02) has met the standards of the “Good Manufacturing Practice for Pharmaceuticals (Revised in 2019)” and successfully passed the GMP certification in one go.

　　The production line that has recently obtained GMP certification is for single-dose eye drops, and the certified product is sodium hyaluronate eye drops. This production line is equipped with world-leading, fully automated “blow-fill-seal” integrated sterile eye-drop manufacturing equipment, with an annual production capacity of 75 million units. The 0.3% single-dose sodium hyaluronate eye drops are indicated for dry eye syndrome and offer the advantages of being sterile and free of preservatives. Currently, the sales volume in China’s market has reached 1.5 billion yuan, with an annual growth rate exceeding 20%, indicating promising market prospects.

　　Currently, Huonland has two ophthalmic drop production lines that have obtained GMP certification, enabling it to simultaneously produce both single-dose and multi-dose ophthalmic drops. This also demonstrates that the subsidiary possesses a robust pharmaceutical quality management system, ensuring that it can provide patients with safe and effective ophthalmic medications. Huonland will actively expand its market presence and create positive social and economic benefits.